Hyperphosphatemia is a common complication in the later stages of chronic kidney disease (CKD). Sequelae can include hypocalcemia, disturbances in bone mineralization homeostasis, and an increased…
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia. Treatment goals…
Acute myeloid leukemia (AML), the most common form of leukemia in adults, is associated with poor five-year overall survival rates. After years of chemotherapy-dominated treatment, the FDA approved…
Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells (RBCs) that distorts them into a sickle shape. This sickling leads to…
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
Rheumatoid arthritis (RA) patients refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitors are generally prescribed a non-TNF targeted therapy (e.g., Bristol-Myers Squibb’s…
As the first agent to be approved for primary biliary cholangitis (PBC), ursodeoxycholic acid (UDCA), which launched nearly two decades ago, transformed the treatment of PBC by greatly reducing…
Hypertriglyceridemia refers to abnormalities in the concentration of triglycerides in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease and, with very high levels…
The chronic obstructive pulmonary disease (COPD) therapy market continues to suffer from the absence of any agents that can reverse disease progression and repair lung tissue. Smoking cessation is…
Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases and is characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand which drugs to…
TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while newer biologics (i.e., Takeda’s…
The systemic sclerosis (SSc) pipeline is replete with therapies targeting pathways underlying autoimmunity, inflammation, and fibrosis, particularly in the early phases of development. Currently,…
Research on the human microbiome is expanding beyond C. difficile, with microbiome-based therapies reaching the clinical trial phase of development for additional disease areas. Investments in this…
The U.S. market for dry eye disease (DED) therapies witnessed notable developments in 2019, including Novartis’s acquisition of Xiidra and the launch of Sun Ophthalmics’ Cequa at a competitive…